NCT04751383 2026-01-21Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaNational Cancer Institute (NCI)Phase 1 Completed12 enrolled 12 charts
NCT04539366 2025-11-03Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST TrialNational Cancer Institute (NCI)Phase 1 Suspended67 enrolled